Document Detail


Fertility outcome following combined methotrexate treatment of unruptured extrauterine pregnancy.
MedLine Citation:
PMID:  10826577     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To assess the effectiveness of systemic treatment with methotrexate in combination with local injection for unruptured tubal pregnancy, and to evaluate reproductive function following treatment. DESIGN: Prospective, open clinical study. SETTING: University clinic. POPULATION: Sixty-seven women with unruptured tubal pregnancy. METHODS: Systemic methotrexate (intramuscular methotrexate 0.5 mg/kg for up to five days) in combination with local application of 12.5 mg methotrexate via laparoscopy. MAIN OUTCOME MEASURES: The subsequent surgical intervention required and future fertility. RESULTS: In 89.6% of women no further surgical intervention was required and 47 women (81%) experienced subsequently an intrauterine pregnancy. In 39 of 40 women who underwent hysterosalpingography following treatment, patency of the affected tube was observed. CONCLUSIONS: Combined local and systemic methotrexate treatment for unruptured tubal pregnancy seems to be more effective than each therapeutic modality alone.
Authors:
A Debby; A Golan; O Sadan; H Zakut; M Glezerman
Related Documents :
20674907 - Race, socioeconomic status, and response to methotrexate treatment of ectopic pregnancy...
1291577 - Transvaginal intratubal insemination, ectopic pregnancy and treatment by single-dose pa...
7647267 - Ectopic pregnancy: new advances in diagnosis and treatment.
11922147 - Medical treatment of ectopic pregnancy using parental methotrexate.
12887287 - Circulating levels of ghrelin in human fetuses.
9159267 - Genetic and environmental parameters for ovulation rate, twinning rate, and weight trai...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  BJOG : an international journal of obstetrics and gynaecology     Volume:  107     ISSN:  1470-0328     ISO Abbreviation:  BJOG     Publication Date:  2000 May 
Date Detail:
Created Date:  2000-06-05     Completed Date:  2000-06-05     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  100935741     Medline TA:  BJOG     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  626-30     Citation Subset:  AIM; IM    
Affiliation:
Department of Obstetrics and Gynaecology, The Edith Wolfson Medical Center, Holon and Sackler Medical School, Tel Aviv, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abortifacient Agents, Nonsteroidal / administration & dosage,  therapeutic use*
Adult
Chorionic Gonadotropin, beta Subunit, Human / metabolism
Combined Modality Therapy
Female
Fertility* / drug effects
Humans
Methotrexate / administration & dosage,  therapeutic use*
Pregnancy
Pregnancy Trimester, First
Pregnancy, Tubal / blood,  drug therapy*,  surgery
Prospective Studies
Salpingostomy
Statistics, Nonparametric
Treatment Outcome
Chemical
Reg. No./Substance:
0/Abortifacient Agents, Nonsteroidal; 0/Chorionic Gonadotropin, beta Subunit, Human; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identifying the indications for laparoscopically assisted vaginal hysterectomy: a prospective, rando...
Next Document:  Reproductive failure in women living in iodine deficient areas of West Africa.